Abstract
Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) improve the survival outcomes of patients with advanced lung adenocarcinoma with common mutations. However, challenges persist in treating rare, uncommon EGFR mutations, such as EGFR S645C, which accounts for only 0.011% of the EGFR mutations in the Guardant360 database. Despite preclinical studies indicating its resistance to osimertinib, we present a case of using afatinib plus bevacizumab to successfully treat a patient with EGFR S645C mutation, for which an effective treatment had not been previously reported. This case report presents real-world evidence for optimal therapeutic options for patients with EGFR S645C mutation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
